This article was originally published in The Gray Sheet
Developer of Grafton demineralized bone matrix announces receipt of FDA 510(k) clearance Jan. 16 for the vertebral body replacement (VBR) system. Osteotech has exclusive distribution rights to the product in the U.S. and Canada. Manufactured by German firm Ulrich & Co., the device is indicated for use in the thoracolumbar apine (T1-L5) to replace a damaged vertebral body. Osteotech expects the product to target a $25 mil. niche of the spinal market
You may also be interested in...
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.
Metabesity is a complex issue that will require a multi-disciplinary approach, concerted effort and clear regulatory pathway to achieve solutions.